B. Valenza

Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

Astrid Lièvre, Anthony Turpin, Isabelle Ray‐Coquard et al. · European Journal of Cancer · 2020 · 163 citations · Full text

Solid Cancer Patients, Cancer Epidemiology, Disease Risk Assessment +12

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled et al. · The Lancet · 2019 · 125 citations

Breast Oncology, Oncology, Early Breast Cancer +6

Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study

Pascal Piedbois, D. Serin, Franck Priou et al. · Annals of Oncology · 2006 · 40 citations · Full text

Node-positive Breast Cancer, Breast Oncology, Reverse Sequence +8

A Weekly Schedule of Docetaxel for Metastatic Hormone-Refractory Prostate Cancer

Jean-­Marc Ferrero, Cyril Foa, Simon Thézenas et al. · Oncology · 2004 · 31 citations

Single-arm phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients over 70 with previously treated metastatic colorectal adenocarcinoma FFCD 1404 – REGOLD

Thomas Aparicio, Ariane Darut‐Jouve, F. Khemissa Akouz et al. · Journal of Geriatric Oncology · 2020 · 21 citations · Full text